๐ Blueprint Medicines: Positive Momentum and Growth Prospects!
๐ Analysis 
BPMC:
Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to its momentum.
๐ Bullish Sentiment:
Entry Range: Suggested entry above the $83.00-$84.00 range.
Upside Target: Aiming for an upside in the $120.00-$125.00 range.
๐ Note: Monitor BPMC's ongoing developments and market performance! ๐๐น #BPMC #Biotech #BullishSentiment ๐๐
BPMC:Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to its momentum.
๐ Bullish Sentiment:
Entry Range: Suggested entry above the $83.00-$84.00 range.
Upside Target: Aiming for an upside in the $120.00-$125.00 range.
๐ Note: Monitor BPMC's ongoing developments and market performance! ๐๐น #BPMC #Biotech #BullishSentiment ๐๐
๋ฉด์ฑ ์ฌํญ
์ด ์ ๋ณด์ ๊ฒ์๋ฌผ์ TradingView์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ธ์ต, ํฌ์, ๊ฑฐ๋ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ๊ณ ์ฌํญ์ ์๋ฏธํ๊ฑฐ๋ ๊ตฌ์ฑํ์ง ์์ต๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ๊ณ ํ์ธ์.